Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study

[1]  Y. Ohe,et al.  Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[2]  K. Jerzak,et al.  ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients , 2018, Supportive Care in Cancer.

[3]  H. Hashimoto,et al.  A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy , 2018, International Journal of Clinical Oncology.

[4]  Jun Zhao,et al.  Evaluation of a Neurokinin-1 Antagonist in Preventing Multiple-day Cisplatin-induced Nausea and Vomiting , 2018, Open medicine.

[5]  J. Leeder,et al.  Aprepitant and fosaprepitant drug interactions: a systematic review , 2017, British journal of clinical pharmacology.

[6]  C. Loprinzi,et al.  Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. , 2016, The New England journal of medicine.

[7]  M. Kris,et al.  Antiemetics: American Society of Clinical Oncology Focused Guideline Update. , 2016, Journal of oncology practice / American Society of Clinical Oncology.

[8]  B. Hutton,et al.  Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea? , 2015, The oncologist.

[9]  N. Masumori,et al.  Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study. , 2014, Journal of pain and symptom management.

[10]  N. Zhou,et al.  Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy‐induced nausea and vomiting in patients receiving multiple‐day cisplatin chemotherapy , 2013, Internal medicine journal.

[11]  R. Navari,et al.  Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. , 2011, The journal of supportive oncology.

[12]  C. Lines,et al.  Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone , 2003, Clinical pharmacology and therapeutics.

[13]  J. Pearson,et al.  Functional relevance of antiemetic control. Experience using the FLIE questionnaire in a randomised study of the NK-1 antagonist aprepitant. , 2003, European journal of cancer.

[14]  J. Pearson,et al.  Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index—Emesis (FLIE) with 5-day recall , 2003, Supportive Care in Cancer.

[15]  M. Aapro,et al.  2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy , 2016, Supportive Care in Cancer.

[16]  E. Demeyer,et al.  Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy. , 2006, The journal of supportive oncology.